Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Adamis Pharmaceuticl (ADMP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 101,972
  • Shares Outstanding, K 27,560
  • Annual Sales, $ 6,470 K
  • Annual Income, $ -19,440 K
  • 36-Month Beta 0.06
  • Price/Sales 16.18
  • Price/Cash Flow 0.00
  • Price/Book 4.90

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.38 +9.47%
on 04/28/17
4.21 -12.11%
on 05/22/17
-0.20 (-5.13%)
since 04/26/17
3-Month
3.20 +15.63%
on 02/27/17
4.80 -22.92%
on 03/14/17
+0.45 (+13.85%)
since 02/24/17
52-Week
2.40 +54.17%
on 10/27/16
9.08 -59.25%
on 06/02/16
-4.81 (-56.52%)
since 05/26/16

Most Recent Stories

More News
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced...

ADMP : 3.70 (-2.63%)
Blog Coverage: Valeant Announces the Pricing for SILIQ as the Lowest Priced Injectable Biologic for Moderate-To-Severe Plaque Psoriasis

Upcoming AWS Coverage on Adamis Pharmaceuticals Post-Earnings Results

VRX.TO : 17.25 (unch)
ADMP : 3.70 (-2.63%)
VRX : 12.83 (+0.31%)
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced...

ADMP : 3.70 (-2.63%)
Adamis (ADMP) Shows Strength: Stock Gains 6.7% in Session

Adamis Pharmaceuticals Corporation (ADMP) moved big last session, as its shares rose over 6% on the day

BCRX : 5.77 (-14.26%)
ADMP : 3.70 (-2.63%)
Adamis Pharmaceuticals (ADMP) Shares March Higher, Can It Continue?

Adamis Pharmaceuticals Corporation (ADMP) has been on the move lately as the stock has risen by 21% in the past four weeks, and it is currently trading well above its 20-Day SMA

ADMP : 3.70 (-2.63%)
Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock?

Investors in Adamis Pharmaceuticals Corporation (ADMP) need to pay close attention to the stock based on moves in the options market lately.

ADMP : 3.70 (-2.63%)
Adamis Pharmaceuticals Announces FDA Acceptance of Resubmission of Its Epinephrine Pre-Filled Syringe NDA

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Company" or "Adamis") today announced that the U.S. Food and Drug Administration ("FDA") has accepted for review the Company's New Drug Application ("NDA")...

ADMP : 3.70 (-2.63%)
Adamis Pharmaceuticals Announces NDA Resubmission of Its Epinephrine Pre-Filled Syringe Application to the FDA

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Company" or "Adamis") today announced the resubmission of the Company's New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA")...

ADMP : 3.70 (-2.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned...

See More

Support & Resistance

2nd Resistance Point 4.00
1st Resistance Point 3.85
Last Price 3.70
1st Support Level 3.60
2nd Support Level 3.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.